Articles

dual antiplatelet therapy, DAPT, mortality, DES implantation, CRF, length

Data from a meta-analysis published recently in The Lancet found that extended-duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with...

Boston Scientific, Watchman LAA device, FDA approval

Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman left atrial appendage closure device. The Watchman device offers a new stroke risk reduction...

atrial fibrillation, women, seniors, guidelines, blood thinners, DCRI

Nearly all women and people over 65 in the United States with atrial fibrillation are advised to take blood thinners under new guidelines based on an analysis from the Duke Clinical Research...

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major...

More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication, according to a new study in the...

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Long-term overtreatment with the anti-clotting drug warfarin combined with antiplatelet therapy to prevent stroke may raise the risk of dementia in people with atrial fibrillation.

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...

Study Blood Thinner Heart Attack Patients

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in...

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was...

U.S. Department of Justice Close Investigation PLATO Clinical Trial Ticagrelor

AstraZeneca announced it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial that tested the safety and...